ROCKVILLE, MD – There is a need for the scientific community to explore the use of additional strength biowaivers for modified release (MR) drugs given the increasing market demand for these “patient ...
Superior efficacy and comparable safety was seen with DFD-29 in patients with rosacea when compared with the current first-line systemic.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果